--- title: "Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings)" type: "News" locale: "en" url: "https://longbridge.com/en/news/274669071.md" description: "Kymera Therapeutics (NASDAQ:KYMR) has received mixed evaluations from 21 analysts over the past three months, with an average 12-month price target of $120.05, reflecting a 44.97% increase from the previous target. Recent ratings show a shift towards bullish sentiments, with several analysts raising their price targets significantly. However, the company faces financial challenges, including a -26.12% decline in revenue growth and a net margin of -2973.05%. Despite these hurdles, Kymera maintains a prudent debt management strategy with a low debt-to-equity ratio of 0.09." datetime: "2026-02-03T14:00:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274669071.md) - [en](https://longbridge.com/en/news/274669071.md) - [zh-HK](https://longbridge.com/zh-HK/news/274669071.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274669071.md) | [繁體中文](https://longbridge.com/zh-HK/news/274669071.md) # Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) During the last three months, 21 analysts shared their evaluations of Kymera Therapeutics (NASDAQ:KYMR), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. **Bullish** **Somewhat Bullish** **Indifferent** **Somewhat Bearish** **Bearish** **Total Ratings** 10 11 0 0 0 **Last 30D** 1 0 0 0 0 **1M Ago** 1 1 0 0 0 **2M Ago** 7 10 0 0 0 **3M Ago** 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $120.05, with a high estimate of $138.00 and a low estimate of $80.00. Observing a 44.97% increase, the current average has risen from the previous average price target of $82.81. ![price target chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ## Exploring Analyst Ratings: An In-Depth Overview A comprehensive examination of how financial experts perceive Kymera Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jeet Mukherjee BTIG Maintains Buy $138.00 $138.00 Etzer Darout Barclays Raises Overweight $133.00 $119.00 Jeet Mukherjee BTIG Maintains Buy $138.00 $138.00 Kalpit Patel B. Riley Securities Raises Buy $117.00 $80.00 Brian Abrahams RBC Capital Raises Outperform $103.00 $70.00 Sudan Loganathan Stephens & Co. Raises Overweight $110.00 $65.00 Joseph Catanzaro Mizuho Raises Outperform $120.00 $81.00 Brian Cheng JP Morgan Raises Overweight $125.00 $70.00 Kelly Shi Jefferies Raises Buy $122.00 $73.00 Geoff Meacham Citigroup Raises Buy $110.00 $80.00 Derek Archila Wells Fargo Raises Overweight $116.00 $69.00 Srikripa Devarakonda Truist Securities Raises Buy $116.00 $80.00 Jeff Jones Oppenheimer Raises Outperform $120.00 $67.00 James Quigley Morgan Stanley Raises Overweight $127.00 $73.00 Etzer Darout Barclays Raises Overweight $119.00 $70.00 Edward Tenthoff Piper Sandler Raises Overweight $125.00 $98.00 Andrew S. Fein HC Wainwright & Co. Raises Buy $134.00 $84.00 Faisal Khurshid Leerink Partners Raises Outperform $118.00 $70.00 Tazeen Ahmad B of A Securities Raises Buy $112.00 $71.00 Jeet Mukherjee BTIG Raises Buy $138.00 $75.00 Srikripa Devarakonda Truist Securities Raises Buy $80.00 $68.00 ### Key Insights: - **Action Taken:** Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company. - **Rating:** Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Kymera Therapeutics compared to the broader market. - **Price Targets:** Understanding forecasts, analysts offer estimates for Kymera Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations. Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kymera Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table. Stay up to date on Kymera Therapeutics analyst ratings. ## About Kymera Therapeutics Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. ### Understanding the Numbers: Kymera Therapeutics's Finances **Market Capitalization Perspectives:** The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale. **Negative Revenue Trend:** Examining Kymera Therapeutics's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately **\-26.12%** in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers. **Net Margin:** Kymera Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of **\-2973.05%,** the company may face hurdles in effective cost management. **Return on Equity (ROE):** Kymera Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of **\-8.57%,** the company may face hurdles in generating optimal returns for shareholders. **Return on Assets (ROA):** Kymera Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of **\-7.36%,** the company may face hurdles in generating optimal returns from its assets. **Debt Management:** With a below-average debt-to-equity ratio of **0.09**, Kymera Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management. ## The Core of Analyst Ratings: What Every Investor Should Know Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are. Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update. In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs. This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Kymera Therapeutics, Inc. (KYMR.US)](https://longbridge.com/en/quote/KYMR.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md) - [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md) - [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md) - [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/en/news/278380208.md) - [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)